novel targeted therapies for nsclc: exploring her2 dysregulation
Published 2 years ago • 262 plays • Length 33:28Download video MP4
Download video MP3
Similar videos
-
36:45
decoding her2 in nsclc: advances in biomarker testing and targeted therapies
-
7:20
treatment of her2 nsclc - 2022 program: targeted therapies forum
-
38:00
continuing the momentum in sclc: exploring second-line and novel therapy options
-
34:12
new and emerging agents in her2-negative metastatic breast cancer: implications for practice
-
47:52
introducing novel immunotherapeutic approaches for metastatic nsclc without driver mutations
-
37:44
deciphering the data in egfr - mutant nsclc
-
3:58
novel targeted therapies in breast cancer
-
3:32
sequencing novel her2-targeted therapies in metastatic breast cancer
-
17:15
her2 targeted therapy for treatment of nsclc
-
3:22
novel approach in targeted treatment
-
31:21
novel therapeutics for breast cancer: her2 and triple negative disease; new pathways, targets
-
9:02
novel therapies in the management of her2-positive breast cancer
-
2:10
novel therapies for the treatment of nsclc: immunotherapy and targeted agents
-
15:09
expanding the reach of her2 in solid tumours: a spotlight on tumour-agnostic approaches
-
55:38
novel therapy for lung cancer: from targeted therapy to immuno-therapy and back again!
-
1:24
novel immunotherapies for colorectal cancer
-
1:43
phase i study of anti-her2 car-engineered monocytes in her2-overexpressing solid tumors
-
5:45
her2-targeted therapy for breast cancer (english)
-
1:58
novel therapies for her2 metastatic breast cancer